Synthesis and biological evaluation of novel allophenylnorstatine-based HIV-1 protease inhibitors incorporating high affinity P2-ligands

Bioorganic and Medicinal Chemistry Letters

Volumn 20, Issue 3, 2010, Pages 1241-1246

  Ghosh, Arun K ^a   Gemma, Sandra ^a   Simoni, Elena ^a   Baldridge, Abigail ^a   Walters, D Eric ^b   Ide, Kazuhiko ^c   Tojo, Yasushi ^c   Koh, Yasuhiro ^c   Amano, Masayuki ^c   Mitsuya, Hiroaki ^c,d  

^a PURDUE UNIVERSITY   (United States)

^b ROSALIND FRANKLIN UNIVERSITY OF MEDICINE AND SCIENCE   (United States)

^c KUMAMOTO UNIV SCHOOL OF MEDICINE   (Japan)

^d HIV   (United States)

Author keywords

Allophenylnorstatine; Darunavir; Design; HIV protease; Inhibitors; Synthesis

Indexed keywords

ALLOPHENYLNORSTATINE; AMPRENAVIR; ANTIVIRUS AGENT; ATAZANAVIR; DARUNAVIR; GRL 02031; GRL 06579; PROTEIN P2; PROTEINASE INHIBITOR; TMC 126; UNCLASSIFIED DRUG; 3-AMINO-2-HYDROXY-4-PHENYLBUTANOIC ACID; ARYLBUTYRIC ACID DERIVATIVE; FURAN DERIVATIVE; HUMAN IMMUNODEFICIENCY VIRUS PROTEINASE; HUMAN IMMUNODEFICIENCY VIRUS PROTEINASE INHIBITOR; LIGAND; P16 PROTEASE, HUMAN IMMUNODEFICIENCY VIRUS 1; PROTEIN BINDING; TETRAHYDROFURAN;

ANTIVIRAL ACTIVITY; ARTICLE; BIOLOGICAL ACTIVITY; CONFORMATION; DRUG PROTEIN BINDING; DRUG SYNTHESIS; ENZYME ACTIVITY; HUMAN IMMUNODEFICIENCY VIRUS 1; NONHUMAN; STEREOCHEMISTRY; ANIMAL; CHEMISTRY; COMPARATIVE STUDY; DRUG SCREENING; HAMSTER; HUMAN; METABOLISM; PHYSIOLOGY; PROCEDURES; STEREOISOMERISM; SYNTHESIS; X RAY CRYSTALLOGRAPHY;

HUMAN IMMUNODEFICIENCY VIRUS 1;

ANIMALS; CRICETINAE; CRYSTALLOGRAPHY, X-RAY; DRUG EVALUATION, PRECLINICAL; FURANS; HIV PROTEASE; HIV PROTEASE INHIBITORS; HUMANS; LIGANDS; PHENYLBUTYRATES; PROTEIN BINDING; STEREOISOMERISM;

EID: 74049090865     PISSN: 0960894X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bmcl.2009.11.123     Document Type: Article

References (27)

1. Sepkowitz K.A. N. Eng. J. Med. 344 (2001) 1764-1772
2. Kohl N.E., Emini E.A., Schleif W.A., Davis L.J., Heimbach J.C., Dixon R.A.F., Scolnick E.M., and Sigal I.S. Proc. Natl. Acad. Sci. U.S.A. 85 (1988) 4686-4690
3. Pillay D., Bhaskaran K., Jurriaans S., Prins M., Masquelier B., Dabis F., Gifford R., Nielsen C., Pedersen C., Balotta C., Rezza G., Ortiz M., de Mendoza C., Kücherer C., Poggensee G., Gill J., and Porter K. AIDS 20 (2006) 21-28
4. Grabar S., Pradier C., Le Corfec E., Lancar R., Allavena C., Bentata M., Berlureau P., Dupont C., Fabbro-Peray P., Poizot-Martin I., and Costagliola D. AIDS 14 (2000) 141-149
5. Wainberg M.A., and Friedland G. JAMA 279 (1998) 1977-1983
6. Ghosh A.K., Kincaid J.F., Cho W., Walters D.E., Krishnan K., Hussain K.A., Koo Y., Cho H., Rudall C., Holland L., and Buthod J. Bioorg. Med. Chem. Lett. 8 (1998) 687-690
7. Koh Y., Maeda K., Ogata H., Bilcer G., Devasamudram T., Kincaid J.F., Boross P., Wang Y.-F., Tie Y., Volarath P., Gaddis L., Louis J.M., Harrison R.W., Weber I.T., Ghosh A.K., and Mitsuya H. Antimicrob. Agents Chemother. 47 (2003) 3123-3129
8. Ghosh A.K., Pretzer E., Cho H., Hussain K.A., and Duzgunes N. Antiviral Res. 54 (2002) 29-36
9. Yoshimura K., Kato R., Kavlick M.F., Nguyen A., Maroun V., Maeda K., Hussain K.A., Ghosh A.K., Gulnik S.V., Erickson J.W., and Mitsuya H. J. Virol. 76 (2002) 1349-1358
10. Ghosh A.K., Sridhar P.R., Leshchenko S., Hussain A.K., Li J., Kovalevsky A.Y., Walters D.E., Wedekind J.K., Grum-Tokars V., Das D., Koh Y., Maeda K., Gatanaga H., Weber I.T., and Mitsuya H. J. Med. Chem. 49 (2006) 5252
11. Koh Y., Das D., Leshchenko S., Nakata H., Ogata-Aoki H., Amano M., Nakayama M., Ghosh A.K., and Mitsuya H. Antimicrob. Agents Chemother. 53 (2009) 997-1006
12. (a) FDA approved Darunavir on June 23, 2006: FDA approved new HIV treatment for patients who do not respond to existing drugs. Please see: http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/2006/ucm108676.htm (b) On October 21, 2008, FDA granted traditional approval to Prezista (darunavir), co-administered with ritonavir and with other antiretroviral agents, for the treatment of HIV-1 infection in treatment-experienced adult patients. In addition to the traditional approval, a new dosing regimen for treatment-naïve patients was approved.
13. Ghosh A.K., Chapsal B.D., Weber I.T., and Mitsuya H. Acc. Chem. Res. 41 (2008) 78-86
14. Ghosh A.K., Ramu Sridhar P., Kumaragurubaran N., Koh Y., Weber I.T., and Mitsuya H. ChemMedChem 1 (2006) 939-950
15. Mimoto T., Terashima K., Nojima S., Takaku H., Nakayama M., Shintani M., Yamaoka T., and Hayashi H. Bioorg. Med. Chem. 12 (2004) 281-293
16. Yoshimura K., Kato R., Yusa K., Kavlick M.F., Maroun V., Nguyen A., Mimoto T., Ueno T., Shintani M., Falloon J., Masur H., Hayashi H., Erickson J., and Mitsuya H. Proc. Natl. Acad. Sci. U.S.A. 96 (1999) 8675-8680
17. Ghosh A.K., Thompson W.J., Holloway M.K., McKee S.P., Duong T.T., Lee H.Y., Munson P.M., Smith A.M., Wai J.M., Darke P.L., Zugay J., Emini E.A., Schleif W.A., Huff J.R., and Anderson P.S. J. Med. Chem. 36 (1993) 2300-2310
18. Ohmoto K., Okuma M., Yamamoto T., Kijima H., Sekioka T., Kitagawa K., Yamamoto S., Tanaka K., Kawabata K., Sakata A., et al. Bioorg. Med. Chem. Lett. 9 (2001) 1307-1323
19. Ikunaka M., Matsumoto J., and Nishimoto Y. Tetrahedron: Asymmetry 13 (2002) 1201-1208
20. Iwona Kudyba I., Raczko J., and Jurczak J. J. Org. Chem. 69 (2004) 2844-2850
21. Ghosh A.K., Duong T.T., and McKee S.P. Tetrahedron Lett. 33 (1992) 2781-2784
22. Ghosh A.K., Leshchenko S., and Noetzel M. J. Org. Chem. 69 (2004) 7822-7829
23. Ghosh A.K., Gemma S., Takayama J., Baldridge A., Leshchenko-Yashchuk S., Miller H.B., Wang Y.-F., Kovalevsky A.Y., Koh Y., Weber I.T., and Mitsuya H. Org. Biomol. Chem. 6 (2008) 3703-3713
24. Ghosh A.K., Gemma S., Baldridge A., Wang Y.-F., Kovalevsky A.Y., Koh Y., Weber I.T., and Mitsuya H. J. Med. Chem. 51 (2008) 6021-6033
25. Toth M.V., and Marshall G.R.A. Int. J. Pep. Protein Res. 36 (1990) 544-550
26. Vega S., Kang L.-W., Velazquez-Campoy A., Kiso Y., Amzel L.M., and Freire E. Proteins 55 (2004) 594-602
27. Kovalevski A.Y., Louis J.M., Aniana A., Ghosh A.K., and Weber I.T. J. Mol. Biol. 384 (2008) 178-192